Jacobs Levy Equity Management
MAZE

Jacobs Levy Equity Management’s Maze Therapeutics MAZE Stock Holding History

Jacobs Levy Equity Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95M Buy
+65,468
New +$1.72M 0.01% 597

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Jacobs Levy Equity Management's MAZE Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Maze Therapeutics (MAZE) in Q2 2026: 65,468 shares worth $1.95M. The stake represents 0.01% of the portfolio and ranks #597 among its holdings.

162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Jacobs Levy Equity Management held 65,468 shares of Maze Therapeutics worth $1.95M as of Q2 2026.
  • Maze Therapeutics was a new Jacobs Levy Equity Management position in Q2 2026.
  • Maze Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #597 holding.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.